Abstract
Tumor necrosis factor-related apoptosis-inducing ligand or Apo2 ligand (TRAIL/Apo2L) is a member of the tumor necrosis factor (TNF) superfamily that induces apoptosis upon binding to its death domain-containing transmembrane receptors. The preferential toxicity of TRAIL to cancer cells and the sparing of normal cells make it an ideal cancer therapeutic agent. TRAIL induces apoptosis via the extrinsic death receptor apoptotic pathway and activates the JNK, ERK, Akt and NF-κB signaling cascades. However, not all cancer cells are sensitive to TRAIL therapy. This may limit its efficacy in the clinic, although ways have already been identified to overcome resistance by combining TRAIL with chemotherapeutic and other biological agents. This review focuses on TRAIL receptor-targeting as anticancer therapy, the apoptotic signaling pathways induced by TRAIL receptors, the prognostic implications of TRAIL receptor expression and modulation by combination therapies. The mechanisms of TRAIL resistance and strategies to overcome drug resistance will also be addressed. Finally, the progress of TRAIL and DR4/DR5-specific agonistic antibodies in clinical trials and the development of new receptor-selective TRAIL variants are discussed including future directions for apoptosis inducing therapy.
Keywords: apoptosis, cancer, DR4, DR5, DcR1, TRAIL, clinical trials, p53, TNF, combination therapy
Current Drug Targets
Title: Targeting Trail Towards the Clinic
Volume: 12 Issue: 14
Author(s): Devalingam Mahalingam, Corina N.A.M. Oldenhuis, Eva Szegezdi, Francis J. Giles, Elisabeth G.E. de Vries, Steven de Jong and Steffan T. Nawrocki
Affiliation:
Keywords: apoptosis, cancer, DR4, DR5, DcR1, TRAIL, clinical trials, p53, TNF, combination therapy
Abstract: Tumor necrosis factor-related apoptosis-inducing ligand or Apo2 ligand (TRAIL/Apo2L) is a member of the tumor necrosis factor (TNF) superfamily that induces apoptosis upon binding to its death domain-containing transmembrane receptors. The preferential toxicity of TRAIL to cancer cells and the sparing of normal cells make it an ideal cancer therapeutic agent. TRAIL induces apoptosis via the extrinsic death receptor apoptotic pathway and activates the JNK, ERK, Akt and NF-κB signaling cascades. However, not all cancer cells are sensitive to TRAIL therapy. This may limit its efficacy in the clinic, although ways have already been identified to overcome resistance by combining TRAIL with chemotherapeutic and other biological agents. This review focuses on TRAIL receptor-targeting as anticancer therapy, the apoptotic signaling pathways induced by TRAIL receptors, the prognostic implications of TRAIL receptor expression and modulation by combination therapies. The mechanisms of TRAIL resistance and strategies to overcome drug resistance will also be addressed. Finally, the progress of TRAIL and DR4/DR5-specific agonistic antibodies in clinical trials and the development of new receptor-selective TRAIL variants are discussed including future directions for apoptosis inducing therapy.
Export Options
About this article
Cite this article as:
Mahalingam Devalingam, N.A.M. Oldenhuis Corina, Szegezdi Eva, J. Giles Francis, G.E. de Vries Elisabeth, de Jong Steven and T. Nawrocki Steffan, Targeting Trail Towards the Clinic, Current Drug Targets 2011; 12 (14) . https://dx.doi.org/10.2174/138945011798829357
DOI https://dx.doi.org/10.2174/138945011798829357 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Neuroprotection after Perinatal Hypoxic-Ischemic Brain Injury
Current Neuropharmacology Pharmacologic Agents for the Treatment of Vasodilatory Shock
Current Pharmaceutical Design Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments
Current Drug Targets Chemical and Clinical Development of Darinaparsin, a Novel Organic Arsenic Derivative
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Discovery of α1-Adrenoceptor Agonists
Current Topics in Medicinal Chemistry Recent Advances in the Treatment of Neurogenic Erectile Dysfunction
Recent Patents on CNS Drug Discovery (Discontinued) Fluoroquinolones, the Cornerstone of Treatment of Drug-Resistant Tuberculosis: A Pharmacokinetic and Pharmacodynamic Approach
Current Pharmaceutical Design Synthesis of Novel Test Compounds for Antiviral Chemotherapy of Severe Acute Respiratory Syndrome (SARS)
Current Medicinal Chemistry Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Genomics of Addiction
Current Psychiatry Reviews Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry Molecular Regulation and Pharmacology of Pacemaker Channels
Current Pharmaceutical Design Scintigraphic Imaging of Inflammatory Processes
Medicinal Chemistry Reviews - Online (Discontinued) Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis
Current Pharmaceutical Design Comparison of Intra and Post-operative Sedation Efficacy of Dexmedetomidinemidazolam and Dexmedetomidine-propofol for Major Abdominal Surgery
Current Drug Metabolism Role of WNK Kinases in Blood Pressure Control
Current Hypertension Reviews Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Current Gene Therapy Antipsychotic Polypharmacy
Current Pharmaceutical Design ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update
Current Pharmaceutical Design Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery